Video

Abiraterone: Approval and Use

Related Videos
Ruben Olivares, MD
Ruben Olivares, MD
Carmen Guerra, MD, MSCE, FACP
Jeffrey P. Townsend, PhD
Robert Dreicer, MD
Alicia Morgans, MD, MPH
Praful K. Ravi, MB, BChir, MRCP
Josep Maria Piulats Rodriguez, MD, PhD
Brendon M. Stiles, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy in early-stage non–small cell lung cancer.
Praful K. Ravi, MB, BChir, MRCP
Related Content
Stefan K. Barta, MD, MS
September 5th 2024

Immunotherapy Could Represent New Treatment Avenue in T-Cell Lymphoma

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

OncLive’s August Roundup of Key FDA Approvals in Oncology
September 4th 2024

OncLive’s August Roundup of Key FDA Approvals in Oncology

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
August 29th 2024

ADT Plus Darolutamide Is Associated With Lower Rates of PSA Progression in nmCRPC

FDA
August 27th 2024

64Cu-SAR-bisPSMA Earns FDA Fast Track Designation for PET Imaging in Prostate Cancer